JP2018521959A - Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション - Google Patents

Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション Download PDF

Info

Publication number
JP2018521959A
JP2018521959A JP2017556585A JP2017556585A JP2018521959A JP 2018521959 A JP2018521959 A JP 2018521959A JP 2017556585 A JP2017556585 A JP 2017556585A JP 2017556585 A JP2017556585 A JP 2017556585A JP 2018521959 A JP2018521959 A JP 2018521959A
Authority
JP
Japan
Prior art keywords
btla
antibody
disease
hvem
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017556585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521959A5 (https=
Inventor
カール エフ． ウェアー，
カール エフ． ウェアー，
ジョン セディー，
ジョン セディー，
ポーラ ノリス，
ポーラ ノリス，
Original Assignee
サンフォード−バーナム メディカル リサーチ インスティテュート
サンフォード−バーナム メディカル リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンフォード−バーナム メディカル リサーチ インスティテュート, サンフォード−バーナム メディカル リサーチ インスティテュート filed Critical サンフォード−バーナム メディカル リサーチ インスティテュート
Publication of JP2018521959A publication Critical patent/JP2018521959A/ja
Publication of JP2018521959A5 publication Critical patent/JP2018521959A5/ja
Priority to JP2022011710A priority Critical patent/JP2022044795A/ja
Priority to JP2024034837A priority patent/JP2024056047A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2017556585A 2015-04-29 2016-04-29 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション Pending JP2018521959A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022011710A JP2022044795A (ja) 2015-04-29 2022-01-28 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
JP2024034837A JP2024056047A (ja) 2015-04-29 2024-03-07 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562154484P 2015-04-29 2015-04-29
US62/154,484 2015-04-29
PCT/US2016/030138 WO2016176583A1 (en) 2015-04-29 2016-04-29 Modulation of immune response using btla agonist antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022011710A Division JP2022044795A (ja) 2015-04-29 2022-01-28 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション

Publications (2)

Publication Number Publication Date
JP2018521959A true JP2018521959A (ja) 2018-08-09
JP2018521959A5 JP2018521959A5 (https=) 2019-05-30

Family

ID=57198828

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017556585A Pending JP2018521959A (ja) 2015-04-29 2016-04-29 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
JP2022011710A Pending JP2022044795A (ja) 2015-04-29 2022-01-28 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
JP2024034837A Pending JP2024056047A (ja) 2015-04-29 2024-03-07 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022011710A Pending JP2022044795A (ja) 2015-04-29 2022-01-28 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
JP2024034837A Pending JP2024056047A (ja) 2015-04-29 2024-03-07 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション

Country Status (4)

Country Link
US (2) US11352428B2 (https=)
EP (1) EP3288587A4 (https=)
JP (3) JP2018521959A (https=)
WO (1) WO2016176583A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022517441A (ja) * 2018-12-17 2022-03-08 オックスフォード ユニヴァーシティ イノヴェーション リミテッド Ｂｔｌａ抗体
JP2022528005A (ja) * 2019-04-01 2022-06-07 レイクファーマ・インコーポレイテッド 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体
JP2023529215A (ja) * 2020-06-11 2023-07-07 オックスフォード ユニバーシティ イノベーション リミテッド Ｂｔｌａ抗体

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3288587A4 (en) 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
CA2990885A1 (en) 2015-06-30 2017-01-05 Sanford-Burnham Medical Research Institute Btla fusion protein agonists and uses thereof
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
JOP20190261A1 (ar) * 2017-05-19 2019-11-05 Lilly Co Eli أجسام مضادة لعامل مساعد لـ btla واستخداماتها
CN113603777B (zh) * 2018-02-12 2022-10-21 原启生物科技(上海)有限责任公司 Il17抗体及其应用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500715A (ja) * 2009-07-31 2013-01-10 メダレックス インコーポレーティッド Ｂｔｌａに対する完全ヒト抗体
WO2015035063A2 (en) * 2013-09-05 2015-03-12 Sanford-Burnham Medical Research Institute MODULATION OF γδT CELLS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1515990T3 (da) * 2002-06-12 2007-06-11 Applied Research Systems Antagonister af CXCR3-bindende CXC chemokiner
US8349320B2 (en) * 2004-12-09 2013-01-08 La Jolla Institute For Allergy And Immunology Compositions and methods for modulating responses mediated or associated with BTLA activity
AU2007278054B2 (en) * 2006-07-24 2012-11-22 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation
US9700606B2 (en) 2008-07-08 2017-07-11 La Jolla Institute For Allergy And Immunology HVEM/BTLA, HVEM/CD 160 and HVEM/gD cis complexes and methods of use
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
EP3288587A4 (en) 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500715A (ja) * 2009-07-31 2013-01-10 メダレックス インコーポレーティッド Ｂｔｌａに対する完全ヒト抗体
WO2015035063A2 (en) * 2013-09-05 2015-03-12 Sanford-Burnham Medical Research Institute MODULATION OF γδT CELLS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IMMUNITY, vol. 39, JPN6020008551, 2013, pages 1082 - 1094, ISSN: 0004428610 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022517441A (ja) * 2018-12-17 2022-03-08 オックスフォード ユニヴァーシティ イノヴェーション リミテッド Ｂｔｌａ抗体
JP2025000681A (ja) * 2018-12-17 2025-01-07 オックスフォード ユニヴァーシティ イノヴェーション リミテッド Ｂｔｌａ抗体
JP2022528005A (ja) * 2019-04-01 2022-06-07 レイクファーマ・インコーポレイテッド 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体
JP7596298B2 (ja) 2019-04-01 2024-12-09 クリア・アイピー・ホールディングス・リミテッド・ライアビリティ・カンパニー 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体
JP2025041629A (ja) * 2019-04-01 2025-03-26 クリア・アイピー・ホールディングス・リミテッド・ライアビリティ・カンパニー 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体
JP2023529215A (ja) * 2020-06-11 2023-07-07 オックスフォード ユニバーシティ イノベーション リミテッド Ｂｔｌａ抗体
JP7486616B2 (ja) 2020-06-11 2024-05-17 オックスフォード ユニバーシティ イノベーション リミテッド Ｂｔｌａ抗体

Also Published As

Publication number Publication date
US11352428B2 (en) 2022-06-07
US20180155426A1 (en) 2018-06-07
EP3288587A1 (en) 2018-03-07
JP2022044795A (ja) 2022-03-17
US20220380468A1 (en) 2022-12-01
EP3288587A4 (en) 2018-09-12
WO2016176583A1 (en) 2016-11-03
JP2024056047A (ja) 2024-04-19

Similar Documents

Publication Publication Date Title
US20220380468A1 (en) Modulation of immune response using btla agonist antibodies
JP7158552B2 (ja) 抗Ｔｉｍ－３抗体及びその使用
JP7366543B2 (ja) Ｂｃｍａ結合分子及びその使用方法
JP2018502044A (ja) 抗ｐｄ−１抗体およびその用途
JP7559013B2 (ja) Ｂｔｌａ融合タンパク質アゴニストおよびその使用
CN114679909A (zh) MAdCAM靶向的免疫耐受
CA3080830A1 (en) Anti-lag-3 antibody and uses thereof
JP7328324B2 (ja) Ｔｉｍ－３に対する抗体およびその使用
CN118702818A (zh) 新型拮抗性抗tnfr2抗体分子
EA043600B1 (ru) Слитые белки btla агонисты и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210720

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211001